AKAP12/Gravin, one of the A-kinase anchoring proteins (AKAPs), functions as a kinase scaffold protein and as a dynamic regulator of the b 2 -adrenergic receptor complex. However, the biological role of AKAP12 in cancer development is not well understood. The AKAP12 gene encodes two major isoforms of 305 and 287 kDa (designated AKAP12A and AKAP12B, respectively, in this report). We found that these two isoforms are independently expressed and that they are probably under the control of two different promoters. Moreover, both isoforms were absent from the majority of human gastric cancer cells. The results from methylation-specific PCR (MSP) and bisulfite sequencing revealed that the 5 0 CpG islands of both AKAP12A and AKAP12B are frequently hypermethylated in gastric cancer cells. Treatment with DNA methyltransferase inhibitor and/or histone deacetylase inhibitor efficiently restored the expression of AKAP12 isoforms, confirming that DNA methylation is directly involved in the transcriptional silencing of AKAP12 in gastric cancer cells. Hypermethylation of AKAP12A CpG island was also detected in 56% (10 of 18) of primary gastric tumors. The restoration of AKAP12A in AKAP12-nonexpressing cells reduced colony formation and induced apoptotic cell death. In conclusion, our results suggest that AKAP12A may function as an important negative regulator of the survival pathway in human gastric cancer.
Introduction
AKAP12/Gravin, one of the A-kinase anchoring proteins (Dell'Acqua and Nauert et al., 1997; Diviani and Scott, 2001; Feliciello et al., 2001) , was first isolated as a protein recognized by serum from myasthenia gravis patients (Gordon et al., 1992) . AKAP12 organizes the complex of PKA and PKC (Nauert et al., 1997) , and is an important regulator of the b 2 -adrenergic receptor complex (Shih et al., 1999; Lin et al., 2000a) . AKAP12 expression can be induced by several drugs like phorbol ester (Gordon et al., 1992; Nauert et al., 1997) and lysophosphatidylcholine (Sato et al., 1998) , which suggests the participation of AKAP12 in diverse signal transduction cascades.
AKAP12 has been mapped to chromosome 6q24-25.2, which frequently contains deletions in tumors, including melanoma (Millikin et al., 1991) and breast cancer (Tibiletti et al., 2000) . Interestingly, the downregulation of AKAP12 expression has been reported in human prostate cancers in vivo (Xia et al., 2001) , suggesting that the inactivation of AKAP12 expression may be linked to oncogenesis. Thus, the molecular mechanism of the tumor-specific inactivation of AKAP12 expression should be defined.
The patterns of DNA methylation and chromatin structure are profoundly altered in neoplasia. Aberrant methylation of the CpG islands located in the promoter regions of tumor suppressor genes (TSGs) is now firmly established as a major epigenetic mechanism of gene inactivation in tumorigenesis (Jones and Laird, 1999; Esteller, 2002; Jones and Baylin, 2002) . Genes silenced by DNA methylation can be restored by treatment with 5-aza-2 0 -deoxycytidine (5-Aza-dC), an inhibitor of DNA methyltransferase (Jones and Taylor, 1980) .
The src-suppressed C-kinase substrate (SSeCKS), the rodent orthologue of human AKAP12, was originally identified as a gene downregulated in response to Src and Ras activation (Lin et al., 1995) . The overexpression of SSeCKS suppressed Src-induced oncogenesis by inhibiting the cellular proliferation, and by reducing anchorage-independent growth in soft agar and invasiveness in Matrigel (Lin and Gelman, 1997) . A recent report showed that SSeCKS regulates blood-brain barrier differentiation by inhibiting angiogenesis by reducing VEGF expression, and that the constitutive expression of SSeCKS may be important for brain homeostasis .
In this study, we identified AKAP12 as a novel epigenetic target gene in gastric cancer, and comparatively evaluated the silencing of the two transcripts of AKAP12. We also examined the tumor suppressor activity of AKAP12A in gastric cancer cells.
Results

Loss of AKAP12 expression in gastric cancer cell line
Northern and Western analyses were performed to examine the expression of AKAP12 in human gastric cancer cells. HepG2 and three gastric cancer cell lines were found to express AKAP12 mRNA and protein, whereas the other cells did not ( Figure 1 ). To determine whether AKAP12 inactivation is due to chromosomal deletion, the genomic DNA at the AKAP12 locus was examined by Southern blot and FISH analysis in gastric cancer cells; however, no genetic defects were detected (data not shown). These cell lines provided a panel of AKAP12-expressing and -nonexpressing cells, and were used to further investigate the mechanism underlying the loss of AKAP12 expression.
Identification of distinct transcripts of AKAP12
The two transcripts of AKAP12 encode three isoforms of 305, 287 and 250 kDa (Xia et al., 2001; Gelman, 2002) . One transcript variant 1 (designated AKAP12A in this study) encodes the large isoform (305 kDa), and another transcript variant 2 (designated AKAP12B in this study) has the small isoform (287 kDa), whereas the M r 250 kDa isoform is a proteolytic cleavage product of these two major isoforms. As shown in Figure 1 , HepG2 and SNU-5 cells expressed three isoforms (305, 287 and 250 kDa) . Two isoforms were detected in SNU-484 (305 and 250 kDa) and . Figure 2a is a schematic diagram of the AKAP12 gene structure based on Genbank database (Accession no. NT_023451). AKAP12A is composed of four exons (1a, 2, 3 and 4), whereas AKAP12B contains three (1b, 3 and 4). To distinguish between the transcripts of AKAP12A and AKAP12B, we performed 5 0 -RACE using primers derived from exon 3, which is common to the two transcripts. All RACE products using the mRNA from SNU-638 encoded exon 1b, but not exon 1a (data not shown), indicating that SNU-638 cells express only AKAP12B. Notably, the upstream of exon 1b was not detected by 5 0 -RACE, suggesting the existence of an internal promoter located at the 5 0 boundary of the coding exon 1b. To characterize the expression profiles Figure 1 Expression of AKAP12A mRNA and protein in gastric cancer cells. Northern blot of total RNA was hybridized with the probe for exon 3 (common to the two AKAP12 transcripts) and subsequently with the b-actin probe as a loading control. The expression of AKAP12 protein was determined by Western blot analysis. A Western blot with anti-Tubulin antibody was used to control for protein content the AKAP12 transcripts by Northern analysis, we designed four kinds of probes specific for each transcript. Probes, P1 and P2, derived from exon 1a and exon 2 were specific for the AKAP12A transcript. P3 derived from exon 1b was specific for the AKAP12B transcript. P4 derived from exon 3 was common to the both transcripts. Figure 2b shows that HepG2 expressed both AKAP12 transcripts, whereas HEK293 and SNU-638 expressed AKAP12A and AKAP12B, respectively. These results imply that both AKAP12 isoforms were missing in the majority of gastric cancer cells.
Aberrant promoter methylation of AKAP12A and AKAP12B in gastric cancer cells During the genetic mapping of AKAP12, we found that AKAP12A and AKAP12B have CpG islands in their promoter regions. The AKAP12A and AKAP12B promoters contained CpG islands of ca. 1.9 kb and 400 bp, respectively (Figure 3a and b). The CpG island in AKAP12A was found to have a GC content of 65.5% and a CpG observed/expected ratio of 0.70, whereas the CpG island in AKAP12B had a GC content of 65.3% and a CpG : GpC ratio of 0.70, thus satisfying the criteria for a CpG island. These findings led us to investigate whether the hypermethylation of the AKAP12 CpG islands could regulate AKAP12 expression in gastric cancer cell lines. Methylation-specific PCR (MSP) assay was used to assess the methylation status of several CpG dinucleotides within the 5 0 CpG islands of both isoforms; examples are illustrated in Figure 3c . MSP analysis for AKAP12A revealed either complete or partial methylation in eight of 11 gastric cancer cell lines. In contrast, three cell lines were unmethylated at the AKAP12A CpG island. In the case of AKAP12B, four cell lines were unmethylated at the AKAP12B CpG island, whereas the remaining seven cell lines were either completely or partially methylated. A close correlation was observed between the expression and methylation status of each CpG island, except in SNU-16 and -668 cells (Figures 1 and 3c ).
Restoration of AKAP12 by 5-Aza-dC treatment
We examined whether demethylation could restore AKAP12 expression in gastric cancer cells. In many cases, treatment with the DNA methyltransferase inhibitor 5-Aza-dC in AKAP12-nonexpressing cells was found to restore AKAP12 expression ( Figure 4a ). Using transcript-specific primers for reverse transcription (RT)ÀPCR analysis ( Figure 4b ), we characterized the expression pattern of each isoform induced by 5-Aza-dC treatment. Western blot using an antibody against AKAP12 showed that the expression levels of the protein correlated well with those of the mRNA (Figure 4c ). To elucidate the kinetic mechanism of 5-Aza-dC-mediated AKAP12 induction in detail, SNU-1 was exposed to increasing concentrations of 5-Aza-dC for 4 days (Figure 4d ), and the re-expression of each AKAP12 isoform was observed at both the mRNA and protein levels in a dose-dependent manner, concurrent with the demethylation of the AKAP12 CpG islands. The methylation patterns of both 17 CpGs of AKAP12A and 23 CpGs of AKAP12B were also examined by bisulfite sequencing (Figure 4e ). All CpG sites within both CpG islands of AKAP12 in SNU-1 were densely methylated. These results obtained from 5-Aza-dC-treated SNU-1 cells revealed that the demethylation of their promoter regions is required to restore AKAP12 expression. Moreover, the methylation status of each CpG island correlated strongly with isoform-specific expression in gastric cancer cells examined.
Aberrant histone deacetylation of AKAP12 in SNU-16 cells
Interestingly, SNU-16 and -668 cells, which did not show AKAP12 expression, were either unmethylated or partially methylated at both AKAP12 CpG islands (Figures 1 and 3c ). In addition, Northern blot analysis showed that the expression of AKAP12 was not recovered by 5-Aza-dC treatment in these cells (Figure 4a) . A growing body of data indicates the importance of histone deacetylation and DNA methylation, and of corresponding chromatin structural alterations in the process of gene silencing (Cameron et al., 1999; Burgers et al., 2002) . To investigate whether aberrant histone deacetylation is involved in AKAP12 silencing in SNU-16 cells, we used 5-Aza-dC and the histone deacetylase inhibitor trichostatin A (TSA), alone or a combination. TSA treatment strongly induced AKAP12B expression in a time-dependent manner, but was unable to restore AKAP12A expression (Figure 5a ). A combination of these two inhibitors induced detectable levels of AKAP12A expression in SNU-16 cells with partial methylation of the AKAP12A CpG islands (Figure 5b ).
Aberrant promoter methylation of AKAP12A in primary gastric cancers
The frequencies of AKAP12A and AKAP12B methylation were then characterized in a small set of gastric cancer tissues and in matched normal tissues (Figure 6a ). The CpG islands of AKAP12A were methylated in 10 of 18 (56%) tumor cases, and those of AKAP12B were methylated in two of 18 (11%). The unmethylated band was always present in tumor samples, most of which (Figure 6b ). All CpG sites in the AKAP12A CpG island were heavily methylated in tumor sample T2, whereas matched normal tissue was unmethylated, suggesting that this hypermethylation is a tumor-specific event. Thus, MSP analysis is sensitive enough to detect very low levels of methylation in the CpG island of AKAP12A. Methylation in normal tissues, which is not the result of imprinting, is frequently 'age-related' (Issa et al., 2001) or represents premalignant changes (Kang et al., 2001) . Next, we examined whether promoter hypermethylation is associated with the downregulation of AKAP12 expression. The downregulation of AKAP12A expression was observed in five of eight gastric tumors by Western blot analysis (Figure 6c ), and three of these five cancer tissues were methylated at the AKAP12A CpG island (Figure 6a ). AKAP12A was expressed in the majority of normal gastric tissues, but its expression was remarkably downregulated in the majority of gastric carcinomas examined.
Growth suppression by AKAP12A restoration
Based on the tumor-specific loss of AKAP12A expression in gastric cancers, we examined whether AKAP12A acts as a tumor suppressor in human gastric cancer cells. The effect of AKAP12A on cancer cell growth was investigated by using a colony formation assay. Plasmid containing wild-type AKAP12A (pAKAP12A), the deletion construct of pAKAP12A (pDAKAP12A) or EGFP (pEGFP) were transiently transfected into AGS cells not expressing AKAP12. The transfection of pAKAP12A significantly reduced (Po0.001) the number of G418-resistant colonies vs pDAKAP12A (Figure 7a) . To obtain more precise information about the function of AKAP12A, we generated several adenoviral vector constructs (Ad), and analysed cell proliferation using an MTT assay 3 days after infection. Compared with Ad-empty and -lacZ control virus, Ad-AKAP12A infection strongly inhibited the cellular growths of AGS (Figure 7b ) and MKN28 (data not shown). Ad-AKAP12B also exhibited growth suppressive activity over the control construct (Ad-empty and Ad-LacZ). FACS analysis was used to further examine the molecular mechanism of growth suppression induced by AKAP12A expression. Cell cycle analysis showed a higher sub-G1 population in Ad-AKAP12A-infected AGS than in control virus-infected AGS (Figure 7c, top) . TUNEL assay and Annexin V staining were used to determine whether the re-expression of AKAP12A induces apoptosis. The transduction of Ad-AKAP12A caused DNA fragmentation (Figure 7c , middle) and a loss of membrane integrity (Figure 7c,  bottom) . Furthermore, the exogenous expression of AKAP12A resulted in the activation of caspase-3 and in the cleavage of PARP (Figure 7d ). These data indicate that the restoration of AKAP12A expression suppresses cell growth by inducing apoptosis in gastric cancer cells.
Discussion
Genetic and epigenetic changes in TSGs are inevitable events in the development of human cancer. Since tumor-acquired promoter hypermethylation and , APC, hMLH1, Rb, VHL, MGMT and BRCA1 (Esteller, 2002) . In the present study, we found that AKAP12 is a target gene for aberrant DNA methylation in gastric cancer cells. Hypermethylation of AKAP12A was detected in 56% of primary tumors, indicating that the inactivation of AKAP12A is relatively common in gastric tumorigenesis.
In our initial study, we observed the loss of AKAP12 expression without genetic deletion in the majority of gastric cancer cells. We then undertook the epigenetic analysis of AKAP12. Two approaches, MSP and bisulfite-sequencing analysis, were used to study the methylation status of the AKAP12 CpG islands. The results showed that the 5 0 CpG islands of both AKAP12A and AKAP12B were frequently hypermethylated in gastric cancer cell lines. Moreover, pharmacologic treatment with DNA methyltransferase inhibitor and/or HDAC inhibitor restored AKAP12 expression in AKAP12-nonexpressing cells, confirming that DNA methylation is directly involved in the transcriptional silencing of AKAP12 in gastric cancer cells.
The CpG island of AKAP12A was partially methylated in SNU-620 and -719 cells, which did not express this gene. As MSP assays are usually carried out in a nonquantitative manner, samples showing only low levels of DNA methylation may be scored as positive for methylation. Nevertheless, methylation does appear to play a role in AKAP12A repression because demethylation readily reactivates the gene (Figure 4 ). In the case of SNU-484 with endogenous expression of AKAP12A, 5-Aza-dC treatment did not affect the level of AKAP12A expression, supporting that DNA methylation is directly involved in the silencing of AKAP12A in SNU-620 and -719 cells. These cells seemed to have a critical threshold level of the methylation necessary to (Conway et al., 2000) , CDH13 (Toyooka et al., 2001 ) and NES1 (Li et al., 2001) . To clarify this, a further examination using the COBRA assay (Xiong and Laird, 1997 ) may be necessary. The inactivation of AKAP12 by other mechanisms, such as point mutations, will also need to be examined to further clarify the role of this gene in cancer development.
Alternative promoters represent other means of generating and regulating diverse protein isoforms. It is not clear whether the two transcripts of AKAP12 arise by different translation initiations from the same mRNA or via transcription from different promoters within the same gene. In our study, 5 0 -RACE and Northern blot analysis results suggested that the expression of each isoform is likely to be regulated by distinct promoters. In addition, the expression of each isotype was strictly regulated by CpG island hypermethylation in each promoter region, supporting the existence of two different promoters. There are similar examples of alternative promoters being the targets of DNA hypermethylation. RASSF1A and RASSF1C are produced by transcription from different promoters, but only RASSF1A was found to be silenced by aberrant methylation in cancers (Dammann et al., 2000 (Dammann et al., , 2001 . In addition, the RIZ1 TSG, but not RIZ2 regulated by the internal promoter of the same gene, was inactivated by DNA hypermethylation in human cancers (Liu et al., 1997; Du et al., 2001) .
Finally, we attempted to introduce AKAP12A expression in AKAP12-nonexpressing cancer cells to determine whether the transformed phenotype could be reduced. In the case of rodent SSeCKS, its overexpression in NIH3T3 fibroblasts caused G1 arrest (Lin et al., 2000b) . However, the growth suppressive activity of AKAP12 has not been studied previously. In the present study, the exogenous expression of AKAP12A in AGS cells reduced colony formation, and this inhibitory effect was mediated by apoptotic cell death. As shown in Figure 7b (MTT assay) and Figure 7c (FACS analysis), the results based on adenoviral expression demonstrated that both AKAP12A and AKAP12B have tumor-suppressive activity. Several pieces of evidence indicate that the function of AKAP12 may be achieved through direct or indirect interaction with multiple effector proteins. These include several signaling molecules, which participate in cell proliferation and cytoskeletal organization, and which include protein kinase C (PKC), protein kinase A (PKA), cyclin D1 and calmodulin (Lin et al., 2000b; Diviani and Scott, 2001; Lin and Gelman, 2002) . AKAP12 was reported to inhibit PKC kinase activity in vitro (Nauert et al., 1997) . Thus, there is a possibility that the loss of AKAP12 expression results in the dysregulation of PKC activity. Since the specific role of AKAP12 in signaling pathway remains unclear, this question should be further explored.
This is the first report to link aberrant DNA methylation to the absence of AKAP12 expression. More importantly, it is the first to suggest, to our knowledge, that the AKAP family is involved in epigenetic alterations. The high incidence of aberrant AKAP12A methylation and its growth suppression activity identified here strongly suggest that AKA12A serves as an important negative regulator of the survival pathway in human gastric cancer. Thus, this gene presents a possible target for therapeutic agents, and may be a useful biomarker for gastric cancer and other cancers. and MKN28, AGS and HepG2 (Korean Cell Line Bank, Seoul, Korea) were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and gentamicin (10 mg/ml). HEK293 (American Type Culture Collection) was maintained in DMEM supplemented with 10% FBS. Tumors and corresponding normal tissues were obtained from 18 patients with primary gastric carcinoma, during surgery at the Seoul National University Hospital, Seoul, Korea.
Materials and methods
Cell lines and tissues
SNU
Northern blot, 5
0 -RACE, RTÀPCR and Western blot analysis
Total and poly(A) RNA were isolated as described previously (Song et al., 2001) . Northern blotting was performed as described previously (Jong et al., 2002) . 5 0 -RACE was carried out on poly(A) RNA using a Marathon cDNA Amplification Kit (Clontech). RACE products were cloned in pCR2.1 TOPO vector (Invitrogen), and sequenced. The genespecific primers (GSP) used were as follows: R1, 5 0 ÀTTAAATCCAATATCATTAGCCTGGGACTCAÀ3 0 (for RT) and R2, 5 0 ÀGATGTCGTGAACAACCGCTGACTTA GTAÀ3 0 (for PCR). RTÀPCR was performed as described previously (Song et al., 2000) . The primer sequences used to prepare the AKAP12 cDNA probes and for RTÀPCR are summarized in Table 1 . Western blotting was performed as described previously (Park et al., 2003) . Polyclonal anti-AKAP12 antibody was a gift from Dr JD Scott (Vollum Institute, Portland, OR, USA). Antibodies against caspase-3, PARP and a-Tubulin were used, as described previously . Detection was performed using an ECL system (Amersham).
Drug treatment and methylation analysis
Cells were incubated in culture medium with 5-Aza-dC (Sigma) at a concentration of 10 mM for 4 days, with medium changes on days 1 and 3, whereas SNU-620 cells were treated with 1 mM of 5-Aza-dC due to cell death at 10 mM. SNU-16 cells were treated with 330 mM TSA (Wako) for various periods, as described in the legend to Figure 5a . For the synergic study, different concentrations of 5-Aza-dC were used in culture for 4 days, and/or the indicated concentrations of TSA detailed in Figure 5b were added for the last 48 h. MSP and bisulfitesequencing analysis were performed as described previously . The primer sequences used for these analyses are summarized in Table 1 .
Colony formation and growth inhibition assay pAKAP12A (a kind gift from Dr JD Scott) was transfected into AGS cells seeded on six-well plates using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's protocol.
The deletion construct of pAKAP12A (pDAKAP12A) was generated by digesting ca. a 4 kb length containing N-terminal region from full cDNA (ca. 5.4 kb) causing the removal of AKAP and PKC binding domains. The resulting peptide encompassed residues 1239-1782 of AKAP12, a fragment containing C-terminal region. pDAKAP12A and pEGFP were used as control plasmids. Cells were trypsinized and plated on six-well plates at 24 h post-transfection. They were then selected with G418 (500 mg/ml), and colonies were counted 11 days after transfection. For the growth inhibition study, AGS cells were plated at a density of 2000 cells/well in 96-well plates, and cell growth inhibition by infection with adenoviral vectors was measured quantitatively by MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide, Sigma) assay, as described previously (Kang et al., 1999) .
Recombinant adenoviral vectors
AKAP12A cDNA was cloned into pShuttle vector (Clontech) for adenoviral vector construction. To construct pShuttle-AKAP12B, the AKAP12A-specific region on pShuttle-AKA-P12A was replaced with an AKAP12B-specific sequence. The expression cassette in each pShuttle vector containing AKA-P12A, AKAP12B or b-galactosidase cDNA was ligated to Adeno-X viral vector (Clontech). These adenoviral vectors were amplified in HEK293 cells, and then CsCl-purified virus was dialysed against PBS with 10% glycerol. The virus titer was determined using a standard plaque assay, and the titer obtained was confirmed using an Adeno-X Rapid titer kit (Clontech). Ad-lacZ was used to monitor the efficiency of transduction by the viral vectors, and as a nonspecific transgene expression control. Adenoviral vector lacking an insert (Ad-empty) was used as a negative control. The transduction efficiency of Ad-lacZ was determined by X-gal staining (Invitrogen).
Cell cycle analysis and apoptosis assay AGS cells were seeded in six-well plates, and infected separately with several adenoviral vector constructs at 20 MOI (multiplicity of infection) in 10% FBS/RPMI, and then incubated at 371 for 2 h with brief agitation every 15 min. The culture medium was then replaced with normal culture medium, and the infected cells were returned to a 371 incubator. FACS analysis using propidium iodide (PI) staining, TUNEL reaction with FITC-labeled dUTP and Annexin V-FITC staining combined with PI staining were performed 48 h after adenoviral infection, as described previously . 
